🇺🇸 FDA
Pipeline program

KL003 Cell Injection

CP-KL003-006/02

Unknown gene_therapy active

Quick answer

KL003 Cell Injection for Sickle Cell Disease is a Unknown program (gene_therapy) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Sickle Cell Disease
Phase
Unknown
Modality
gene_therapy
Status
active

Clinical trials